Abstract

BackgroundType 2 diabetes mellitus increases the risk of cardiovascular disease including myocardial infarction (MI). Inflammation and apoptosis have been implicated in the pathophysiology of MI. In the present study, the effects of astragaloside IV (AS-IV) on MI in diabetic mice were evaluated.MethodsHigh glucose/high fat (HG/HF) and hypoxia culture condition were established to mimic diabetic condition. After administration of AS-IV to H9c2 myocytes, the cell apoptosis, viability, and activation of mitogen-activated protein kinase (MAPK) signaling pathways were detected. MI was induced in streptozotocin-induced diabetic mice. After administration of AS-IV to mice, cardiac function, cardiac fibrosis, inflammation, and activation of MAPK signaling pathway were detected.ResultsAstragaloside IV treatment significantly inhibited HG/HF and hypoxia-induced apoptosis of H9c2. AS-IV inhibited activation of JNK and p38 signaling pathway while promoting the activation of EKR signaling pathway. AS-IV treatment rescued cardiac function, suppressed cardiac fibrosis and inflammation, and differently regulated the activation of MAPK signaling pathways.ConclusionAstragaloside IV prevented apoptosis and restored cardiac function in MI, which may be due to the regulation of MAPK signaling pathway in diabetes.

Highlights

  • Type 2 diabetes mellitus (T2DM) is a metabolic disorder with high blood sugar (DeFronzo et al, 2015)

  • Low- and high-dose astragaloside IV (AS-IV) treatment significantly decreased the percentage of apoptotic cells in a dose-dependent manner, indicating that AS-IV prevented high fat (HF)/high glucose (HG) and hypoxia-induced apoptosis

  • Similar results were obtained using CCK-8 assay (Figure 1C). These results demonstrated that AS-IV prevented HG/HF and hypoxia-induced apoptosis in H9c2 myocytes

Read more

Summary

Introduction

Type 2 diabetes mellitus (T2DM) is a metabolic disorder with high blood sugar (DeFronzo et al, 2015). T2DM results in multiple clinical complications including diabetic cardiomyopathy, retinopathy, nephropathy, and neuropathy (Zheng et al, 2018). Myocardial infarction (MI) is a common cardiac disease caused by decreased or stopped blood flow to the heart (Anderson and Morrow, 2017). Compared with patients without diabetes, patients with T2DM have greater mortality and morbidity during MI and post infarction (Jacoby and Nesto, 1992). The precise relationship between MI and diabetes needs further elucidation (Lu et al, 2020). Type 2 diabetes mellitus increases the risk of cardiovascular disease including myocardial infarction (MI). The effects of astragaloside IV (AS-IV) on MI in diabetic mice were evaluated

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call